Ventilatory responses to @entity519 (HVR) and hypercapnic (HCVR) stimuli in relation with @entity935 (DA) and @entity22770 precursor @entity9191 ( @entity9191 ) venous blood content were studied in healthy @entity1 aged 55-65 years (Gr. 1) and @entity191 ( @entity191 ) @entity1 without (Gr. 2) and with (Gr. 3) @entity3034 treatment under intermittent @entity519 training (IHT, three identical daily isocapnic, progressive, @entity519 rebreathing sessions separated by 5-minute breaks for 14 consecutive days). HVR in Gr. 2, when compared to Gr. 1, was 48% lower showing almost linear @entity734 and was accompanied by lower levels of blood @entity9191 and DA content (26% and 20%, respectively). HVR in Gr. 3 was only 17% lower compared to Gr. 1 and was accompanied by higher levels of blood @entity9191 and DA content (40% and 147%, respectively). No differences in HCVR between groups were registered. IHT produced a 75% increase in HVR in Gr. 1 (p < 0.05), 52% augmentation of HVR in Gr. 2 (p < 0.05, at that the curves became hyperbolic in shape), and 2.2-fold increase in Gr. 3 (p < 0.01). The augmentation of @entity519 sensitivity under IHT was accompanied by significant decrease in @entity9191 blood concentration in Gr. 1 and Gr. 3, although no changes in Gr. 2 were observed. It was no changes in DA blood content in all groups. IHT produced no significant changes in HCVR. This investigation confirms the conception that @entity191 is accompanied by DA deficit not only in basal ganglia but also in peripheral chemoreceptors provoking a decrease in @entity519 ventilatory sensitivity. @entity191 does not influence on hypercapnic sensitivity. @entity3034 -treatment as well as IHT improve the functioning of respiratory system, increase HVR and do not influence on HCVR. The method of IHT can be involved in complex therapy of @entity191 .

[Respiratory regulation during adaptation to intermittent XXXX in @entity1 with @entity191 ].

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity3034 :: ('MESH:D007980', 'Chemical') :: ['L-DOPA'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity22770 :: ('MESH:C025953', 'Chemical') :: ['DAs'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's disease", 'PD'] @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxic'] @entity9191 :: ('MESH:D004295', 'Chemical') :: ['dihydroxy phenylalanine', 'DOPA'] @entity734 :: ('MESH:D019966', 'Disease') :: ['dependence']
@entity519 :: (MESH:D000860,Disease) :: ['hypoxia']
